HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oreal Appoints Research, Innovation And Tech Head; Shiseido’s First Female Regional CEO; Beauty Exec News

Executive Summary

Beginning in February 2021, Barbara Lavernos, chief technologies and operations officer at L’Oreal, will be president of research, innovation and technologies, a role that CEO Jean-Paul Agon says is crucial to the company’s BeautyTech future. More beauty industry people news.

You may also be interested in...



L’Oreal Names CEO To Follow Agon; ELC And Coty Appoint Digital Leadership; Executive News In Brief

Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.

COVID-19 Vaccine Authorization In Adolescents Would Raise Questions Around Routine Immunizations

US FDA not planning an advisory committee for Pfizer/BioNTech’s request for authorization in 12-15-year olds at this time, but CDC’s ACIP is likely to weigh how to balance timing of COVID vaccination with administration of other immunizations generally recommended for adolescents.

Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers

HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.

Topics

UsernamePublicRestriction

Register

RS150565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel